Does the media favor BEAM or EDIT?

In the previous week, Editas Medicine had 6 more articles in the media than Beam Therapeutics. MarketBeat recorded 18 mentions for Editas Medicine and 12 mentions for Beam Therapeutics. Editas Medicine's average media sentiment score of 1.10 beat Beam Therapeutics' score of 1.07 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EDIT or CRSP?

In the previous week, Editas Medicine had 10 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 18 mentions for Editas Medicine and 8 mentions for CRISPR Therapeutics. Editas Medicine's average media sentiment score of 1.10 beat CRISPR Therapeutics' score of 0.77 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EDIT or NTLA?

In the previous week, Editas Medicine had 9 more articles in the media than Intellia Therapeutics. MarketBeat recorded 18 mentions for Editas Medicine and 9 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.12 beat Editas Medicine's score of 1.10 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXRX or EDIT?

In the previous week, Editas Medicine had 8 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 18 mentions for Editas Medicine and 10 mentions for Recursion Pharmaceuticals. Editas Medicine's average media sentiment score of 1.10 beat Recursion Pharmaceuticals' score of 0.86 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SNDX or EDIT?

In the previous week, Editas Medicine had 7 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 18 mentions for Editas Medicine and 11 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.65 beat Editas Medicine's score of 1.10 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Editas Medicine 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Editas Medicine (EDIT) Competitors

$3.16 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$3.12 -0.04 (-1.27%)

As of 04:32 AM Eastern

Compare

EDIT vs. BEAM, CRSP, NTLA, RXRX, and SNDX

Should you buy Editas Medicine stock or one of its competitors? Editas Medicine's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Recursion Pharmaceuticals (RXRX), and Syndax Pharmaceuticals (SNDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Editas Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Beam Therapeutics has a net margin of -54.75% compared to Editas Medicine's net margin of -157.32%. Beam Therapeutics' return on equity of -30.71% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Editas Medicine	-157.32%	-196.63%	-38.17%

Beam Therapeutics currently has a consensus price target of $49.00, indicating a potential upside of 67.12%. Editas Medicine has a consensus price target of $5.50, indicating a potential upside of 74.05%. Given Editas Medicine's higher possible upside, analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Editas Medicine had 6 more articles in the media than Beam Therapeutics. MarketBeat recorded 18 mentions for Editas Medicine and 12 mentions for Beam Therapeutics. Editas Medicine's average media sentiment score of 1.10 beat Beam Therapeutics' score of 1.07 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.67	-$79.99M	-$0.86	N/A
Editas Medicine	$40.52M	11.98	-$160.06M	-$0.75	N/A

Summary

Beam Therapeutics beats Editas Medicine on 11 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to CRISPR Therapeutics?

Editas Medicine (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	11.98	-$160.06M	-$0.75	N/A
CRISPR Therapeutics	$3.51M	1,590.01	-$581.60M	-$4.76	N/A

Editas Medicine has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Editas Medicine has a net margin of -157.32% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Editas Medicine currently has a consensus price target of $5.50, suggesting a potential upside of 74.05%. CRISPR Therapeutics has a consensus price target of $68.06, suggesting a potential upside of 17.91%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

In the previous week, Editas Medicine had 10 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 18 mentions for Editas Medicine and 8 mentions for CRISPR Therapeutics. Editas Medicine's average media sentiment score of 1.10 beat CRISPR Therapeutics' score of 0.77 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Editas Medicine beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Intellia Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, Editas Medicine had 9 more articles in the media than Intellia Therapeutics. MarketBeat recorded 18 mentions for Editas Medicine and 9 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.12 beat Editas Medicine's score of 1.10 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has higher earnings, but lower revenue than Intellia Therapeutics. Editas Medicine is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	11.98	-$160.06M	-$0.75	N/A
Intellia Therapeutics	$67.67M	26.65	-$412.69M	-$3.36	N/A

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Editas Medicine has a net margin of -157.32% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Editas Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

Editas Medicine currently has a consensus target price of $5.50, indicating a potential upside of 74.05%. Intellia Therapeutics has a consensus target price of $21.15, indicating a potential upside of 64.35%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Intellia Therapeutics beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Editas Medicine has lower revenue, but higher earnings than Recursion Pharmaceuticals. Editas Medicine is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	23.94	-$644.76M	-$1.04	N/A
Editas Medicine	$40.52M	11.98	-$160.06M	-$0.75	N/A

Recursion Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Recursion Pharmaceuticals currently has a consensus target price of $8.06, suggesting a potential upside of 141.32%. Editas Medicine has a consensus target price of $5.50, suggesting a potential upside of 74.05%. Given Recursion Pharmaceuticals' higher possible upside, research analysts clearly believe Recursion Pharmaceuticals is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Editas Medicine has a net margin of -157.32% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Editas Medicine	-157.32%	-196.63%	-38.17%

In the previous week, Editas Medicine had 8 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 18 mentions for Editas Medicine and 10 mentions for Recursion Pharmaceuticals. Editas Medicine's average media sentiment score of 1.10 beat Recursion Pharmaceuticals' score of 0.86 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Editas Medicine beats Recursion Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Syndax Pharmaceuticals has a net margin of -87.52% compared to Editas Medicine's net margin of -157.32%. Editas Medicine's return on equity of -196.63% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Editas Medicine	-157.32%	-196.63%	-38.17%

Syndax Pharmaceuticals has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

In the previous week, Editas Medicine had 7 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 18 mentions for Editas Medicine and 11 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.65 beat Editas Medicine's score of 1.10 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Editas Medicine	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.9% of Editas Medicine shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Editas Medicine has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.05	-$285.42M	-$2.51	N/A
Editas Medicine	$40.52M	11.98	-$160.06M	-$0.75	N/A

Syndax Pharmaceuticals currently has a consensus price target of $41.55, suggesting a potential upside of 112.62%. Editas Medicine has a consensus price target of $5.50, suggesting a potential upside of 74.05%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Editas Medicine beats Syndax Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDIT vs. The Competition

Export

Metric	Editas Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$485.31M	$3.94B	$7.18B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-4.21	11.68	273.17	25.45
Price / Sales	11.98	1,408.89	638.21	103.75
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	11.29	16.92	11.08	6.36
Net Income	-$160.06M	-$22.74M	$3.48B	$349.79M
7 Day Performance	5.33%	-0.13%	0.38%	-0.40%
1 Month Performance	22.48%	11.45%	7.89%	4.24%
1 Year Performance	22.96%	55.66%	24.71%	15.13%

Editas Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDIT Editas Medicine	2.0521 of 5 stars	$3.16 flat	$5.50 +74.1%	+23.0%	$485.31M	$40.52M	N/A	230	Trending News Analyst Revision
BEAM Beam Therapeutics	2.0853 of 5 stars	$31.03 +9.5%	$49.00 +57.9%	+79.2%	$2.93B	$139.74M	N/A	510	Positive News
CRSP CRISPR Therapeutics	2.1191 of 5 stars	$60.90 +6.7%	$68.06 +11.7%	+11.4%	$5.52B	$3.51M	N/A	460	Gap Up
NTLA Intellia Therapeutics	3.0108 of 5 stars	$13.51 +7.6%	$21.15 +56.6%	+13.4%	$1.76B	$67.67M	N/A	600	Gap Up
RXRX Recursion Pharmaceuticals	1.8803 of 5 stars	$3.56 +9.5%	$8.06 +126.4%	-28.9%	$1.74B	$74.68M	N/A	400	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDIT) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, RXRX, and SNDX

How does Editas Medicine compare to Beam Therapeutics?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Summary

How does Editas Medicine compare to Recursion Pharmaceuticals?

Summary

How does Editas Medicine compare to Syndax Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, RXRX, and SNDX

How does Editas Medicine compare to Beam Therapeutics?

Do insiders & institutionals have more ownership in BEAM or EDIT?

Is BEAM or EDIT more profitable?

Do analysts recommend BEAM or EDIT?

Does the media favor BEAM or EDIT?

Which has more volatility & risk, BEAM or EDIT?

Which has preferable valuation & earnings, BEAM or EDIT?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Do insiders and institutionals hold more shares of EDIT or CRSP?

Which has preferable valuation and earnings, EDIT or CRSP?

Which has more volatility & risk, EDIT or CRSP?

Is EDIT or CRSP more profitable?

Do analysts rate EDIT or CRSP?

Does the media favor EDIT or CRSP?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Does the media prefer EDIT or NTLA?

Which has stronger earnings & valuation, EDIT or NTLA?

Do institutionals and insiders believe in EDIT or NTLA?

Is EDIT or NTLA more profitable?

Which has more volatility & risk, EDIT or NTLA?

Do analysts prefer EDIT or NTLA?

Summary

How does Editas Medicine compare to Recursion Pharmaceuticals?

Which has stronger earnings & valuation, RXRX or EDIT?

Which has more volatility and risk, RXRX or EDIT?

Do analysts prefer RXRX or EDIT?

Is RXRX or EDIT more profitable?

Does the media refer more to RXRX or EDIT?

Do institutionals & insiders hold more shares of RXRX or EDIT?

Summary

How does Editas Medicine compare to Syndax Pharmaceuticals?

Is SNDX or EDIT more profitable?

Which has more volatility and risk, SNDX or EDIT?

Does the media favor SNDX or EDIT?

Do institutionals and insiders hold more shares of SNDX or EDIT?

Which has stronger valuation and earnings, SNDX or EDIT?

Do analysts recommend SNDX or EDIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools